Preslava M. Hristova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Preslava M. Hristova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Sashova Alexandrova
Department of Medical Microbiology, Medical Faculty, Medical University of Sofia, Zdrave str. 2, 1431 Sofia, Bulgaria
1 shared publication - Hristina Hitkova
Department of Microbiology and Virology, Medical University of Pleven, 5800 Pleven, Bulgaria
1 shared publication - Hristina Yotova Hitkova
Department of Microbiology and Virology, Medical University of Pleven, 5800 Pleven, Bulgaria
1 shared publication - Kalina Mihova
Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University of Sofia, 1431 Sofia, Bulgaria
1 shared publication - Nikolay Kirilov Balgaranov
Department of Pediatric Diseases, Medical University of Pleven, 5800 Pleven, Bulgaria
1 shared publication - Polya Marinovska
Department of Microbiology and Virology, Medical University of Pleven, 5800 Pleven, Bulgaria
1 shared publication
Latest Publications
- Open Access
- 24 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1618
Genotypic and Phenotypic Resistance Profiles of Invasive Acinetobacter baumannii Isolates at Bulgarian University Hospital
Acinetobacter baumannii is a formidable nosocomial pathogen responsible for severe hospital-acquired infections. This study aimed to investigate the relationship between genotypic and phenotypic resistance profiles in 36 non-duplicate invasive A. baumannii isolates collected at a tertiary care hospital in Bulgaria over a six-year period (2019–2024). Identification was performed by MALDI-TOF MS and PCR-based detection of blaOXA-51-like and gyrB. Antimicrobial susceptibility testing to ten agents was performed by gradient diffusion and broth microdilution, and selected resistance genes were detected by conventional PCR. Whole-genome sequencing of 17 representative isolates was conducted to confirm the resistance genotype–phenotype associations and perform MLST. Carbapenem resistance was detected in 34/36 isolates (94.4%), mediated by blaOXA-23-like (29/34) or blaOXA-72 (5/34). The armA gene associated with high-level resistance to all three aminoglycosides was identified exclusively in blaOXA-23-like-positive isolates (18/29). In armA-negative isolates, gentamicin and tobramycin MICs decreased markedly, whereas amikacin MICs remained elevated. In addition, minocycline MICs ≥ 8 mg/L were observed in the presence of armA. Seven distinct genotypic–phenotypic profiles were defined based on these gene–MIC associations. Resistome and phylogenetic analyses confirmed these relationships, with MLST assigning the isolates to established clonal lineages ST2 and ST636 (International Clone II). These findings support the use of targeted genes, such as armA, combined with phenotypic testing to guide empirical therapy and strengthen local surveillance of high-risk A. baumannii clones in hospital settings.
- 24 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1618
Open AccessGenotypic and Phenotypic Resistance Profiles of Invasive Acinetobacter baumannii Isolates at Bulgarian University Hospital
Acinetobacter baumannii is a formidable nosocomial pathogen responsible for severe hospital-acquired infections. This study aimed to investigate the relationship between genotypic and phenotypic resistance profiles in 36 non-duplicate invasive A. baumannii isolates collected at a tertiary care hospital in Bulgaria over a six-year period (2019–2024). Identification was performed by MALDI-TOF MS and PCR-based detection of blaOXA-51-like and gyrB. Antimicrobial susceptibility testing to ten agents was performed by gradient diffusion and broth microdilution, and selected resistance genes were detected by conventional PCR. Whole-genome sequencing of 17 representative isolates was conducted to confirm the resistance genotype–phenotype associations and perform MLST. Carbapenem resistance was detected in 34/36 isolates (94.4%), mediated by blaOXA-23-like (29/34) or blaOXA-72 (5/34). The armA gene associated with high-level resistance to all three aminoglycosides was identified exclusively in blaOXA-23-like-positive isolates (18/29). In armA-negative isolates, gentamicin and tobramycin MICs decreased markedly, whereas amikacin MICs remained elevated. In addition, minocycline MICs ≥ 8 mg/L were observed in the presence of armA. Seven distinct genotypic–phenotypic profiles were defined based on these gene–MIC associations. Resistome and phylogenetic analyses confirmed these relationships, with MLST assigning the isolates to established clonal lineages ST2 and ST636 (International Clone II). These findings support the use of targeted genes, such as armA, combined with phenotypic testing to guide empirical therapy and strengthen local surveillance of high-risk A. baumannii clones in hospital settings.
- Open Access
- 16 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9028
Population Genetic Structure of Invasive and Non-Invasive Streptococcus pneumoniae Isolates After Fifteen Years of Routine PCV10 Vaccination in Bulgaria
Streptococcus pneumoniae has been a PCV10 vaccine-preventable agent in Bulgaria since 2010. Our objective is to determine the phylogenetic structure of 170 invasive and non-invasive pneumococcal isolates, focusing on their serotypes and antimicrobial susceptibility. Serotyping was performed using latex agglutination, capsular swelling reaction, and serotype-specific PCRs. Antibiotic susceptibilities were assessed by broth microdilution. MLST was conducted to define the clonal composition. The non-PCV10 serotypes accounted for 88.2%. The predominant invasive pneumococcal disease (IPD) serotypes were 19A (39.3%), 19F (21.4%), 6C (10.7%), 7F (7.1%), and 3 (7.1%). The prevalent NIPD serotypes were 19A (18.3%), 6C (15.5%), 3 (10.6%), 15A (7.7%), and 6A (6.3%). The overall antimicrobial non-susceptibility rates were: benzylpenicillin (55.2%), ceftriaxone (15.2%), cefuroxime (35.8%), amoxicillin-clavulanic acid (38.8%), erythromycin (60.5%), clindamycin (57.0%), tetracycline (43.5%), trimethoprim-sulfamethoxazole (62.9%), and chloramphenicol (13.5%). The multidrug resistance (MDR) strains were 60.5%. The predominant clone CC320, represented 20.0% MDR 19A and 19F strains linked to Taiwan19F-14 and GPSC1. CC273/Greece6B-22 and CC386 accounted for 5.3% 6A and 6C isolates. Most serotype 3 isolates are associated with CC505, associated with Netherlands3-31 and GPSC12. Switching to a conjugate vaccine with broader serotype coverage could reduce the incidence of 19A, 6C, and 15A MDR S. pneumoniae clones in our country.
- 16 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9028
Open AccessPopulation Genetic Structure of Invasive and Non-Invasive Streptococcus pneumoniae Isolates After Fifteen Years of Routine PCV10 Vaccination in Bulgaria
Streptococcus pneumoniae has been a PCV10 vaccine-preventable agent in Bulgaria since 2010. Our objective is to determine the phylogenetic structure of 170 invasive and non-invasive pneumococcal isolates, focusing on their serotypes and antimicrobial susceptibility. Serotyping was performed using latex agglutination, capsular swelling reaction, and serotype-specific PCRs. Antibiotic susceptibilities were assessed by broth microdilution. MLST was conducted to define the clonal composition. The non-PCV10 serotypes accounted for 88.2%. The predominant invasive pneumococcal disease (IPD) serotypes were 19A (39.3%), 19F (21.4%), 6C (10.7%), 7F (7.1%), and 3 (7.1%). The prevalent NIPD serotypes were 19A (18.3%), 6C (15.5%), 3 (10.6%), 15A (7.7%), and 6A (6.3%). The overall antimicrobial non-susceptibility rates were: benzylpenicillin (55.2%), ceftriaxone (15.2%), cefuroxime (35.8%), amoxicillin-clavulanic acid (38.8%), erythromycin (60.5%), clindamycin (57.0%), tetracycline (43.5%), trimethoprim-sulfamethoxazole (62.9%), and chloramphenicol (13.5%). The multidrug resistance (MDR) strains were 60.5%. The predominant clone CC320, represented 20.0% MDR 19A and 19F strains linked to Taiwan19F-14 and GPSC1. CC273/Greece6B-22 and CC386 accounted for 5.3% 6A and 6C isolates. Most serotype 3 isolates are associated with CC505, associated with Netherlands3-31 and GPSC12. Switching to a conjugate vaccine with broader serotype coverage could reduce the incidence of 19A, 6C, and 15A MDR S. pneumoniae clones in our country.